Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026)
Zymeworks recorded quarterly Non-Current Deferred Tax Liability of $3.8 million in Q1 2026, down 36.51% quarter-over-quarter from $6.0 million in Q4 2025, and down 20.52% year-over-year from $4.8 million in Q1 2025.
Zymeworks' Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $3.8 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 20.52% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 20.52% YoY), while the FY2025 annual figure was $6.0 million, up 26.61% from the prior year.
- Non-Current Deferred Tax Liability came in at $3.8 million for Q1 2026 at Zymeworks, down from $6.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $6.0 million in Q4 2025 to a low of $1.6 million in Q3 2022.
- A 5-year average of $3.4 million and a median of $3.4 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability tumbled 87.32% in 2022 and surged 84.56% in 2023, its largest moves.
- Zymeworks' Non-Current Deferred Tax Liability stood at $1.8 million in 2022, then soared by 84.56% to $3.3 million in 2023, then jumped by 44.27% to $4.8 million in 2024, then gained by 26.61% to $6.0 million in 2025, then sank by 36.51% to $3.8 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.8 million, $6.0 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.83 Mn |
| Mar 31, 2026 | 3.83 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.30 Mn |
| Dec 31, 2023 | 3.30 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.86 Mn |
| Mar 31, 2023 | 1.86 Mn |
| Dec 31, 2022 | 1.79 Mn |
| Dec 31, 2022 | 1.79 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Dec 31, 2021 | 14.10 Mn |
| Dec 31, 2021 | 14.10 Mn |